35 LIMS & Lab Automation
The minimum data set that is necessary for accurate and effi cient ASV is not generally defi ned. However, this same audience mostly agreed that HRMS and 1D 1H NMR data, which can both be obtained relatively quickly, are generally necessary. Whereas more time-consuming experiments such a 1D 13C NMR, 2D NMR, and chromatography may be skipped, particularly for structures that are previously known.
But this doesn’t mean that those working with novel structures cannot benefi t from ASV. For this subset, the benefi ts of databasing spectral data are immediate and real. While no commercial database will contain the novel structures being investigated in your organisation. The accuracy of NMR prediction for novel chemical space can be improved with the addition of even small amounts of your own curated data.
“Accurate prediction is very important for our automated structure verifi cation process and we’ve seen excellent results from training the NMR predictors DB with or own data over the years.”
Celine Nguyen-van-dau, Sanofi The Path to ASV is Made Up of Many Steps
With the ever-increasing number of stories of automation in scientifi c workfl ows, it’s easy to feel intimidated and overwhelmed. However, while some organisations have begun to adopt and benefi t from ASV, we found that most of our Structure Elucidation & Verifi cation Symposium audience (70%) are still only doing manual structure verifi cation. All the while, 20% have less that half of their structure verifi cation automated and only 5% reported fully automated structure verifi cation.
At the same time, we asked this audience where they were in their journey towards automated data analysis, including ASV. The large majority (77%) reported that they are adopting automation, with most being in the early or middle stages of their implementation.
While only 7% report using automation in their daily workfl ows, they are not the only ones reaping the benefi ts of automation. The overall time savings of even partially automated structure elucidation and verifi cation can add up quickly in a variety of environments.
In open-access labs, minimised experiment time frees up instrument time and can distribute analysis time savings across a variety of diverse teams within an organisation. Similarly, the large quantity of samples in high-throughput structure verifi cation workfl ows mean the time and resources saved with ASV can be substantial.
So, while modern workfl ows still rely heavily on manual structure determination, it appears that the industry is overwhelmingly in favour of adopting automated data analysis to free up scientists’ time for more novel pursuits.
For those in a similar situation to almost a quarter of the audience who have no immediate plans to automate their data analysis, it’s essential to recognise that the gap between organisations embracing automation and those lagging behind will continue to widen. Therefore, now is an opportune moment to consider how ASV can help alleviate bottlenecks in your workfl ows.
For decades, ACD/Labs has been committed to supporting scientifi c experts from many of the world’s leading biopharmaceutical and chemical companies in identifying, verifying, and elucidating chemical structures.
Our experts and fl exible software solutions can help you strategically build towards your organisation’s automated data analysis goals.
Read, Share and Comment on this Article, visit:
www.labmate-online.com Document Management System for Life Sciences Collaboration and Compliance
Kivo has introduced Kivo GO, a unified platform designed to facilitate efficient collaboration for emerging life sciences teams while maintaining compliance and security.
Emerging companies managing new drugs and devices often find themselves navigating a complex landscape of trials and approvals, with stringent compliance requirements from regulatory authorities. Their Regulatory, Clinical, and Quality teams face significant challenges due to patchwork systems, manual processes, and unnecessary delays. A recent McKinsey study has quantified the cost of each day of delay at $1 million in lost potential revenue.
Toban Zolman, the CEO of Kivo, emphasises the critical importance of time-to-market for new treatments, both for the patients who need them and the companies sponsoring these innovations. Smaller Regulatory, Clinical, and Quality teams often lack the budget and administrative resources for large-scale enterprise solutions, leading to considerable time losses in managing documents and processes compliantly.
To address these challenges, Kivo GO offers a compliant collaboration solution equipped with integrated modules for functions such as RIM, eTMF, and QMS. Kivo GO offers several significant advantages.
Kivo GO streamlines collaboration for Regulatory, Clinical, and Quality teams, as well as partners and vendors, within a secure workspace, eliminating the need for complex integrations. Designed and priced with smaller teams in mind, Kivo GO provides an all-in-one solution at an affordable price, offering fast setup, lifetime updates, and real-time support. Every team member can access the same workspace and functional modules. Kivo GO places a strong emphasis on best-in-class security and compliance. It is Part 11 Compliant and Validated, requiring no local installation and offering built- in support for Single Sign-On. Kivo, as a fit-for-purpose, cloud-based system, is equipped with automatic guardrails and audit trails to ensure data integrity and compliance.
The launch of Kivo GO also marks the expansion of Kivo’s Quality Management (QMS) capabilities, introducing new modules for SOPs, Controlled Documents, Training, CAPAs, Vendor Management, Audits, and more. These modules leverage templates, workflows, reporting, and project management features integrated into the Kivo GO platform.
Kivo GO is not limited to in-house teams. It extends its capabilities to vendors and partners, allowing CROs and regulatory consultants to standardise their process and project management. This enables them to work more efficiently and consistently with sponsor teams.
More information online:
ilmt.co/PL/9j51 61438pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
